pyrazines has been researched along with 2,3-dinor-6-ketoprostaglandin f1alpha in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Edlund, A; Musatti, L; Wennmalm, A | 1 |
1 trial(s) available for pyrazines and 2,3-dinor-6-ketoprostaglandin f1alpha
| Article | Year |
|---|---|
Acipimox stimulates skin blood flow by a cyclo-oxygenase-dependent mechanism.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Cyclooxygenase Inhibitors; Female; Hemodynamics; Humans; Hypolipidemic Agents; Male; Pyrazines; Regional Blood Flow; Skin; Skin Temperature | 1990 |